eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2020
vol. 16
 
Share:
Share:
more
 
 
abstract:
Letter to the Editor

Response to Letter to the Editor “Adverse outcomes in anticoagulated patients undergoing percutaneous left atrial appendage ligation” by Anetta Undas

Radoslaw Litwinowicz
1
,
Dhanunjaya Lakkireddy
2
,
Boguslaw Kapelak
1
,
Krzysztof Bartus
1

1.
Department of Cardiovascular Surgery and Transplantology, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland
2.
The Kansas City Heart Rhythm Institute, Overland Park Regional Hospital, University of Kansas, Kansas, USA
Adv Interv Cardiol 2020; 16, 2 (60): 233–234
Online publish date: 2020/06/23
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
We thank Prof. Undas for her interest in our recent article and comments on left atrial appendage occlusion [1]. We agree that our study indirectly points to potential benefits of non-vitamin K oral anticoagulants’ (NOAC) use in selected atrial fibrillation (AF) patients following left atrial appendage occlusion (LAAO) in the setting of high thromboembolic and bleeding risk, but a dedicated study is urgently needed to support this concept. Several points need to be discussed.
We presented the real-life observational data on different anticoagulation strategies in atrial fibrillation (AF) patients after LAAO using the LARIAT system between 2009 and 2015 [1]. During this period, the guidelines on oral anticoagulation in AF shifted towards the novel drugs. NOACs were approved in adults with non-valvular AF at the end of 2011, and 18% of patients studied by us received drugs from this group at the end of the study (2015). We observed a progressive increase in NOAC use starting from 2012–2013, which is in concordance with other Polish data [2]. The fraction of patients receiving NOACs is rather small, which may be a result of the relative unfamiliarity of LAAO procedure concepts, and/or reluctance to use drugs new to the market.
Unfortunately, detailed data on the quality of anticoagulation were unavailable in the current report, but poor quality of anticoagulant therapy is a well-known problem in AF patients. In Poland, the time within the therapeutic range (TTR) in primary care patients on vitamin K antagonist (VKA) therapy is around 55% [3], and some of the observed adverse events may, arguably, be caused by poor VKA anticoagulation management. Two hemorrhagic strokes were observed in non-anticoagulated patients and were probably caused by uncontrolled hypertension. The first of those patients, with a CHA2DS2-VASc score of 6 points and a HAS-BLED score of 3 points, was managed with aspirin. In the second patient, with a CHA2DS2-VASc score of 2 points and a HAS-BLED score of 2 points, no anticoagulation or antiplatelet drugs were given. In the OAC group a hemorrhagic stroke occurred in 1 patient on VKA, with a CHA2DS2-VASc score of 2 points and a HAS-BLED score of 3 points, who had INR > 3.5 (after this event, anticoagulation was discontinued completely). There was also one case of gastrointestinal bleeding in a NOAC-treated patient with a CHA2DS2-VASc score of 6 points and a HAS-BLED score of 5 points (the dose of dabigatran was reduced...


View full text...
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe